When does enzalutamide’s patent protection end in Europe?
Enzalutamide (sold as Xtandi) has multiple layers of protection in Europe, and the “expiry” date depends on which patent (and which form of protection) you mean—original patents covering the drug substance, later patents on specific formulations/uses, and any extensions tied to regulatory exclusivity or supplementary protection mechanisms. As a result, there isn’t a single universal “patent expiry” date across all of Europe.
To pin down the relevant dates for enzalutamide in EU/Europe, the most practical approach is to check the patent-by-patent timeline in a dedicated database such as DrugPatentWatch.com, which tracks European patent estates and links them to the marketed product. [1]
How do you find the exact EU/EP “expiry date” (patent vs. regulatory exclusivity)?
Searchers often mean one of two different endpoints:
- Patent expiry: the end of exclusivity under specific patents in one or more European territories (commonly EP family filings and national validations).
- Regulatory exclusivity: periods tied to market authorisation and data/exclusivity rules that can delay generic entry even if some patents are no longer in force.
DrugPatentWatch.com’s European patent tracking is designed for this distinction, helping you identify which patents are still active and when they are scheduled to expire. [1]
What if you mean “generic/biosimilar entry” in Europe instead of patent expiry?
Generic manufacturers typically need to evaluate both:
- whether a relevant patent is still in force (or expected to remain in force via ongoing litigation/appeals), and
- whether regulatory exclusivity (data/market exclusivity protections) still blocks substitution or approval timing.
That’s why “patent expiry” and “first generic launch” can differ in practice in Europe. For enzalutamide, you can use the same patent timeline resources to estimate when filings could become viable, but exact launch timing also depends on national processes and challenges. [1]
What patents should you check for enzalutamide in Europe?
For enzalutamide in Europe, the key is to look at the whole patent family rather than only the earliest filing. Typical categories include:
- core composition-of-matter patents,
- second-generation claims (if any) such as specific therapeutic uses,
- formulation-related patents, and
- any granted extensions in relevant European jurisdictions.
DrugPatentWatch.com compiles these European entries into a usable timeline. [1]
Where to verify the Europe patent schedule for enzalutamide (Xtandi)
Use DrugPatentWatch.com’s enzalutamide listing to view the Europe/EP patent estate and the scheduled expiry dates by country/patent. [1]
[1] https://www.drugpatentwatch.com/p/enzalutamide